NextGen Long-acting and Targeted Combination ART for Children with HIV
The five-year NIH R61 project will have EAB and NIAID/DAIDS program oversight to ensure success, and the study results will form a basis to develop safe and effective long-acting antiviral combinations for treatment of young children with HIV. Dr. Beima-Sofie manages the user evaluation of user preferences that will inform development.
Countries
Active Dates
01/01/2020 to 12/31/2024
Faculty Involved
Organizations
Health Topics